Autonomix Medical(US:AMIX) Globenewswire·2026-03-05 13:45Core Insights - Autonomix Medical, Inc. has been selected for an oral presentation at the Best Innovation Competition during the Cardiovascular Research Technologies (CRT) 2026 conference, showcasing its innovative technology for nerve-targeted treatments [1][2]. Company Overview - Autonomix is a medical device company focused on developing advanced technologies for diagnosing and treating diseases related to the nervous system. Its first-in-class platform includes a catheter-based microchip sensing array designed to detect and differentiate neural signals with greater sensitivity than existing technologies [4]. - The company aims to enable transvascular diagnosis and treatment of peripheral nervous system diseases, potentially revolutionizing patient care [4]. Technology and Applications - The initial focus of Autonomix's technology is on treating pain associated with pancreatic cancer, a condition known for causing severe pain and lacking reliable treatment options. The technology is also positioned to address various other indications, including cardiology, hypertension, and chronic pain management [5]. - The investigational technology has not yet received marketing clearance in the United States [5]. Presentation Details - The presentation will be delivered by CEO Brad Hauser on March 9, 2026, emphasizing the scientific innovation and clinical relevance of the company's approach to nerve treatment [2][3]. - The CRT Best Innovation Competition is recognized for highlighting transformative technologies that can significantly impact patient care [2].